Endoscopy 2008; 40(3): 184-191
DOI: 10.1055/s-2007-995426
Original article

© Georg Thieme Verlag KG Stuttgart · New York

Early closure of a multicenter randomized clinical trial of endoscopic stenting versus surgery for stage IV left-sided colorectal cancer

J.  E.  van Hooft1 , P.  Fockens1 , A.  W.  Marinelli2 , R.  Timmer3 , A.  M.  van Berkel4 , P.  M.  Bossuyt5 , W.  A.  Bemelman6 , on behalf of the Dutch Colorectal Stent Group[1]
  • 1Department of Gastroenterology and Hepatology, Academic Medical Center, Amsterdam, The Netherlands
  • 2Department of Surgery, Medical Center Haaglanden, Den Haag, The Netherlands
  • 3Department of Gastroenterology and Hepatology, St Antonius Hospital, Nieuwegein, The Netherlands
  • 4Department of Gastroenterology and Hepatology, Rode Kruis Hospital, Beverwijk, The Netherlands
  • 5Department of Clinical Epidemiology and Bio-statistics, Academic Medical Center, Amsterdam, The Netherlands
  • 6Department of Surgery, Academic Medical Center, Amsterdam, The Netherlands
Further Information

Publication History

submitted 11 September 2007

accepted after revision 24 October 2007

Publication Date:
06 March 2008 (online)

Background and study aims: The introduction of self-expandable metal stents has offered a promising alternative for palliation of malignant left-sided colonic obstruction. This randomized clinical trial aimed to assess whether a nonsurgical policy, with endoluminal stenting, is superior to surgical treatment in patients with stage IV left-sided colorectal cancer and imminent obstruction.Patients and methods: Patients with incurable left-sided colorectal cancer who fulfilled the study criteria were randomly assigned to nonsurgical or surgical treatment. The primary outcome measure was survival in good health out of hospital (World Health Organization performance scores 0 or 1).Results: A high number of serious adverse events in the nonsurgical arm led to premature closure of the trial. Ten patients were allocated to surgical treatment and 11 patients to nonsurgical palliation. The median survival in good health out of hospital during the first year was 56 days (interquartile range 7.5 - 338.5 days) in the surgical arm vs. 38 days (interquartile range 5.25 - 288.75 days) in the nonsurgical arm (P = 0.68). Eleven adverse events (six perforations) occurred in the nonsurgical arm vs. one adverse event in the surgical arm (P < 0.001). Of the six perforations, two were stent-related because they occurred at the proximal edge of the stent by erosion through a normal colon wall; one was probably stent-related (it was located in the region of the proximal half of the stent); one was a colon blowout; and two were late tumor perforations in patients on chemotherapy.Conclusions: The unexpected high rate of perforation in the nonsurgical arm might be specifically WallFlex-related or enteral stent-related in patients on chemotherapy and warrants attention.

References

  • 1 Parkin D M, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002.  CA Cancer J Clin. 2005;  55 74-108
  • 2 CCCnet. Comprehensive Cancer Centers 2005 .Available from: http://www.ikcnet.nl/cijfers/index.php
  • 3 Harris G J, Senagore A J, Lavery I C, Fazio V W. The management of neoplastic colorectal obstruction with colonic endoluminal stenting devices.  Am J Surg. 2001;  181 499-506
  • 4 Allen-Mersh T G, Earlam S, Fordy C. et al . Quality of life and survival with continuous hepatic-artery floxuridine infusion for colorectal liver metastases.  aLancet. 1994;  344 1255-1260
  • 5 Cunningham D, Pyrhonen S, James R D. et al . Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer.  Lancet. 1998;  352 1413-1418
  • 6 Meyerhardt J A, Mayer R J. Systemic therapy for colorectal cancer.  N Engl J Med. 2005;  352 476-487
  • 7 Scheithauer W, Rosen H, Kornek G V. et al . Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer.  BMJ. 1993;  306 752-755
  • 8 Smyth J F, Hardcastle J D, Denton G. et al . Two phase III trials of tauromustine (TCNU) in advanced colorectal cancer.  Ann Oncol. 1995;  6 948-949
  • 9 Dohmoto M, Rupp K D, Hohlbach G. Endoscopically-implanted prosthesis in rectal carcinoma [in German, no abstract].  Dtsch Med Wochenschr. 1990;  115 915
  • 10 Tejero E, Mainar A, Fernandez L. et al . New procedure for the treatment of colorectal neoplastic obstructions.  Dis Colon Rectum. 1994;  37 1158-1159
  • 11 Sebastian S, Johnston S, Geoghegan T. et al . Pooled analysis of the efficacy and safety of self-expanding metal stenting in malignant colorectal obstruction.  Am J Gastroenterol. 2004;  99 2051-2057
  • 12 Khot U P, Lang A W, Murali K, Parker M C. Systematic review of the efficacy and safety of colorectal stents.  Br J Surg. 2002;  89 1096-1102
  • 13 Johnson R, Marsh R, Corson J, Seymour K. A comparison of two methods of palliation of large bowel obstruction due to irremovable colon cancer.  Ann R Coll Surg Engl. 2004;  86 99-103
  • 14 Law W L, Choi H K, Chu K W. Comparison of stenting with emergency surgery as palliative treatment for obstructing primary left-sided colorectal cancer.  Br J Surg. 2003;  90 1429-1433
  • 15 Xinopoulos D, Dimitroulopoulos D, Theodosopoulos T. et al . Stenting or stoma creation for patients with inoperable malignant colonic obstructions? Results of a study and cost-effectiveness analysis.  Surg Endosc. 2004;  18 421-426
  • 16 Fiori E, Lamazza A, de CA . et al . Palliative management of malignant rectosigmoidal obstruction. Colostomy vs. endoscopic stenting: a randomized prospective trial.  Anticancer Res. 2004;  24 265-268
  • 17 Carne P W, Frye J N, Robertson G M, Frizelle F A. Stents or open operation for palliation of colorectal cancer: a retrospective, cohort study of perioperative outcome and long-term survival.  Dis Colon Rectum. 2004;  47 1455-1461
  • 18 Hurwitz H, Fehrenbacher L, Novotny W. et al . Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.  N Engl J Med. 2004;  350 2335-2342
  • 19 Kabbinavar F F, Schulz J, McCleod M. et al . Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial.  J Clin Oncol. 2005;  23 3697-3705
  • 20 Karoui M, Charachon A, Delbaldo C. et al . Stents for palliation of obstructive metastatic colon cancer: impact on management and chemotherapy administration.  Arch Surg. 2007;  142 619-623
  • 21 Aaronson N K, Ahmedzai S, Bergman B. et al . The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology.  J Natl Cancer Inst. 1993;  85 365-376
  • 22 Lamers L M, McDonnell J, Stalmeier P F. et al . The Dutch tariff: results and arguments for an effective design for national EQ-5D valuation studies.  Health Econ. 2006;  15 1121-1132
  • 23 van Hooft J E, Fockens P, Marinelli A W. et al . Premature closure of the Dutch Stent-in I study.  Lancet. 2006;  368 1573-1574
  • 24 Athreya S, Moss J, Urquhart G. et al . Colorectal stenting for colonic obstruction: the indications, complications, effectiveness and outcome: 5-year review.  Eur J Radiol. 2006;  60 91-94
  • 25 Suzuki N, Saunders B P, Thomas-Gibson S. et al . Colorectal stenting for malignant and benign disease: outcomes in colorectal stenting.  Dis Colon Rectum. 2004;  47 1201-1207
  • 26 Duda S H, Wiskirchen J, Tepe G. et al . Physical properties of endovascular stents: an experimental comparison.  J Vasc Interv Radiol. 2000;  11 645-654
  • 27 Dyet J F, Watts W G, Ettles D F, Nicholson A A. Mechanical properties of metallic stents: how do these properties influence the choice of stent for specific lesions?.  Cardiovasc Intervent Radiol. 2000;  23 47-54
  • 28 Stoeckel D, Pelton A, Duerig T. Self-expanding nitinol stents: material and design considerations.  Eur Radiol. 2004;  14 292-301
  • 29 Palliative chemotherapy for advanced or metastatic colorectal cancer. Colorectal Meta-analysis Collaboration.  Cochrane Database Syst Rev. 2000;  CD001545
  • 30 Costi R, Mazzeo A, di MD . et al . Palliative resection of colorectal cancer: does it prolong survival?.  Ann Surg Oncol. 2007;  14 2567-2576
  • 31 Konyalian V R, Rosing D K, Haukoos J S. et al . The role of primary tumour resection in patients with stage IV colorectal cancer.  Colorectal Dis. 2007;  9 430-437
  • 32 Kuo L J, Leu S Y, Liu M C. et al . How aggressive should we be in patients with stage IV colorectal cancer?.  Dis Colon Rectum. 2003;  46 1646-1652
  • 33 Liu S K, Church J M, Lavery I C, Fazio V W. Operation in patients with incurable colon cancer: is it worthwhile?.  Dis Colon Rectum. 1997;  40 11-14
  • 34 Ruo L, Gougoutas C, Paty P B. et al . Elective bowel resection for incurable stage IV colorectal cancer: prognostic variables for asymptomatic patients.  J Am Coll Surg. 2003;  196 722-728
  • 35 Tekkis P P, Poloniecki J D, Thompson M R, Stamatakis J D. Operative mortality in colorectal cancer: prospective national study.  BMJ. 2003;  327 1196-1201
  • 36 Targownik L E, Spiegel B M, Sack J. et al . Colonic stent vs. emergency surgery for management of acute left-sided malignant colonic obstruction: a decision analysis.  Gastrointest Endosc. 2004;  60 865-874

1 See Appendix

W. A. Bemelman, MD, PhD 

Academic Medical Center
Department of Surgery

Meibergdreef 9
1105 AZ Amsterdam
The Netherlands

Fax: +31-206914858

Email: W.A.Bemelman@amc.nl

    >